Navigation Links
HUYA Bioscience International Announces A Strategic Alliance With The Korea Drug Development Fund
Date:11/30/2015

SAN DIEGO, Nov. 30, 2015 /PRNewswire/ -- HUYA Bioscience International, the leader in accelerating global development of China's pharmaceutical innovations, today announced it has signed a Memorandum of Understanding with the Korea Drug Development Fund (KDDF) to foster collaboration between KDDF and HUYA with the ultimate goal of advancing Korean development and commercialization of healthcare products for the global market.

HUYA is the first company to have recognized China's potential as an important source of new innovative preclinical and clinical stage compounds. The company advances the development and value creation for China-sourced novel biopharmaceutical compounds in worldwide markets. HUYA has already established more than 100 agreements with leading universities and research institutes throughout China as a pioneer in the licensing of both preclinical and clinical stage compounds from the country. Now the company will expand that effort to include Korea in partnership with the KDDF.

"This partnership is particularly exciting given Korea's emerging biotechnology products coupled with HUYA's mission and track record in bringing drug candidates from Asia for global development, said Mireille Gillings, Ph.D., CEO of HUYA. "We look forward to great success from this alliance in the coming years." "We are very pleased about working with the KDDF adding to our activities in China and Japan" said Clem Gingras CTO and COO of Asia. "We now have strategic alliances in all three countries involved in the Tripartite Cooperation Treaty."

KDDF's CEO, Sang Aun Joo, M.D., Ph.D. said, "We are expecting that adding more promising drug candidates via the strategic alliance with HUYA would deliver substantial performance for Korean pharmaceutical R&D to maximize global licensing-out opportunities and to enter global new drug development arena" 

About HUYA Bioscience International
HUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan and eight strategic locations across China, with joint headquarters in San Diego and Shanghai. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. Earlier this year, HUYA was named the winner of a Stevie® Award in the Health Products & Services and Pharmaceuticals category in the Asia-Pacific Stevie Awards. 
www.huyabio.com

About the Korea Drug Development Fund (KDDF) 
Signaling a new change in government-funded strategy, the KDDF was established in 2011 and operates through close management of development projects, linking grant support to the achievement of milestone-based research objectives. With a budget of US$1 billion, including private matching funds, the KDDF is an unparalleled response to the clinical demands of the 21st century. This investment in the country's future is aimed at nurturing success that is initially driven by government and then transformed into a sustainable growth engine through valued researchers and industry partners. For more information, please visit http://www.kddf.org

Contact details: 
Yiota Merianos 
HUYA Corporate Communications 
+1.858.353.1217 
ymerianos@huyabio.com

Photo - http://photos.prnewswire.com/prnh/20151129/291518

 


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Aytu BioScience to Present at Two Upcoming Investor Conferences
2. Neurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference
3. Twist Bioscience To Present At The 2015 Piper Jaffray Healthcare Conference
4. Representative Scott Peters Visits Avelas Biosciences
5. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
6. Proove Biosciences Appoints Eric Fung, M.D. Ph.D., as Chief Scientific Officer
7. Pressure BioSciences, Inc. to Discuss Third Quarter 2015 Financial Results and Provide Business Update
8. Proove Biosciences Launches Monthly Real World Evidence Webinars to Educate Physicians on Proove Genetic Testing™
9. Pressure BioSciences, Inc. Reports Record Third Quarter and Year-to-Date 2015 Financial Results and Provides Business Update
10. Roka Bioscience Reports Third Quarter 2015 Financial Results
11. Keck Graduate Institute (KGI), A Member of the Los Angeles County Bioscience Coalition Will Be Working with Partners to Develop a Regional Bioscience Industry Cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2018)... ... August 28, 2018 , ... Cognition Corporation ®, ... lineup of talks for NAVIGATE2018 . , Ryan Ward, Director of Engineering ... annual user conference. An experienced engineer and manager with Zimmer Biomet for almost 15 ...
(Date:8/29/2018)... ... August 28, 2018 , ... LabRoots , the ... the world, is proud to announce the launch of a new gamification feature, allowing ... chance to win one of LabRoots most popular shirts. , Throughout each month, LabRoots ...
(Date:8/26/2018)... ... 24, 2018 , ... ExoCoBio Inc., based in South Korea, ... and inhibits a variety of inflammatory targets in the journal of Stem Cell ... having severe atopic dermatitis were significantly improved after administration of stem cell-derived exosomes ...
(Date:8/21/2018)... ... August 21, 2018 , ... ... and commercialization, has just released a new paper discussing systems engineering for ... Mario Kossmann, ESEP at the 28th Annual INCOSE International Symposium, the paper ...
Breaking Biology Technology:
(Date:9/15/2018)... ... 2018 , ... The first ever production picosecond-domain laser with a 785?nm wavelength ... tattoo inks - often the colors most resistant to laser removal. , A clinical ... American Society for Laser Medicine and Surgery, Inc. (ASLMS) investigated the safety and efficacy ...
(Date:9/12/2018)... PARK, Calif. (PRWEB) , ... September 10, 2018 ... ... that a paper detailing the performance of its new Multiplexed Ion Beam Imaging ... the September 6 issue. This study will also be shared during a webinar ...
(Date:9/12/2018)... ... September 12, 2018 , ... JoVE, the ... pleased to support the professional development of academic librarians by sponsoring four award-winners ... entrants were asked to submit successful strategies to increase collaboration among librarians and ...
Breaking Biology News(10 mins):